34 cases of familial exudative vitreoretinopathy were seen during a 40-month period ending April 1981. There were 30 cases from 11 families and 4 sporadic cases. The familial cases showed the mode of inheritance compatible with the autosomal-dominant in heritance. Ophthalmoscopy and super-wide panoramic fluorescein angiography revealed characteristic retinal vascular abnormalities in all cases, embracing supernumerous vascular branchings, arteriovenous shunt formation in the extreme periphery, generalized hyperpermeability of vessels and incomplete arteriovenous interdigitating pattern. Vitreoretinal adhesion was present in the peripheral temporal retina in all cases. An avascular zone wider than 1 disc diameter was noted in the majority of cases in the extreme temporal periphery. A V-shaped retinal degeneration was seen along the temporal meridian in 18 cases (48%). Retinal detachment was present in 19 eyes of 14 cases, and it was rhegmatogenous in 11 and traction-induced in 8 eyes. Retinal exudates and total posterior vitreous detachment was seen only occasionally.

Keywords:
Familial exudative vitreoretinopathy, Retinal degeneration, Retinal detachment, Retinal vessels, Retrolental fibroplasia
This content is only available via PDF.
© 1982 S. Karger AG, Basel
1982
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.